Tim Lewis
SVP, Strategic Development
Expertise:
Tim has served as a strategic lead to healthcare companies for more than 25 years in advertising, marketing, and finance roles in agency and client settings. His work spans pre-clinical to sunset strategies and from brand infrastructure to digital roadmaps. He has helped stand up clinical trial recruitment efforts at the franchise level, primarily in the oncology space. This work has involved establishing corporate standards around managing PHI and PII across markets and trials. Tim has also worked on numerous oncology launch brands as well as repositioning mid-cycle brands for growth. He has built his career as a trusted counselor in healthcare, providing deep knowledge of customer preferences and trends in the life science vertical.
A regular author and speaker on topics of interest to the healthcare industry, Tim currently leads organization-level initiatives across business strategy and development.
Articles by Tim Lewis
The Combination Crossfire: Is Your Brand Strategy Strong Enough to Align Payers, Prescribers, and Patients?
Navigating Oncology’s Combination Era Combination therapy is now the norm in oncology, with most trials exploring multi-drug regimens. Success depends not just on clinical results, but on how well your brand stands out and performs within these complex combinations. One Value Story, Three Audiences Today’s oncology marketers must master the art of translation—crafting a core […]
A New Marketing Mandate in Community Oncology
As the next wave of oncology innovation—bispecific antibodies, ADCs, and CAR-T therapies—moves from academic centers into community practices, marketers face unprecedented clinical, operational, and financial hurdles. Success now demands a shift from traditional promotion to building tailored support ecosystems that empower every practice, regardless of size or location. Our Marketing Toolkit for Community Oncology That’s […]
The Enablement Helix: An Evolving Framework for Market Success in Oncology
In today’s rapidly evolving oncology landscape, market success demands more than traditional promotional strategies – it requires a unified, cross-functional approach that empowers clinical partners and streamlines care delivery. EVERSANA’s dynamic framework, The Enablement Helix, redefines how brands engage with healthcare professionals by integrating three key strands into one seamless strategy: Breakthrough Creative […]
Redefining CAR-T Access: Strategic Implications of the FDA’s REMS Decision
The FDA’s removal of REMS requirements for BCMA- and CD19-directed CAR-T therapies marks a pivotal regulatory milestone—reducing administrative burdens and opening the door to broader patient access. But the real opportunity lies in how manufacturers respond to a growing pipeline of CAR-T candidates competing for limited treatment center capacity. As clinical efficacy alone is no […]
Empowering Scientific Dialogue: Key Takeaways from the FDA’s SIUU Guidance
Discover the latest insights from the FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU). This comprehensive document provides a clarified framework for pharmaceutical companies to share scientifically sound information with healthcare providers. In this article, our EVERSANA ONCOLOGY experts explore how to align strategy with compliance while maximizing the impact of data across […]
Navigating the Final FDA SIUU Guidance: Strategic Considerations for Scientific Exchange at ASCO and Other Congresses
The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA ONCOLOGY’s experts explore how to align strategy with compliance while maximizing the impact of data across a variety of scientifically sound […]
FDA Guidance and Considerations for Scientific Exchange Communication Strategies
In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk and opportunity for more informative conversations between pharmaceutical manufacturer representatives and healthcare providers (HCPs) regarding the care of individual […]